<DOC>
	<DOCNO>NCT02326311</DOCNO>
	<brief_summary>In phase III clinical randomize study , `` fix '' intermittent administration ( one month ON/one month OFF ) TKIs ( control arm ) , compare `` progressive '' intermittent administration ( one month ON/one month OFF 1st year ; one month ON/two month OFF 2nd year ; one month ON/three month OFF 3rd year ) ( experimental arm ) . Imatinib ( Glivec ) , Nilotinib ( Tasigna ) , Dasatinib ( Sprycel ) give intermittently daily dose give daily time enrollment . Chronic phase Ph+ CML patient stable major molecular response ( MR3.0 MR4.0 ) ≥2 year standard treatment IM , NIL , DAS randomize 1:1 receive `` fix '' INTERIM `` progressive '' INTERIM . Randomization stratify type TKI ( IM , NIL , DAS , ) depth molecular response ( MR3.0or MR4.0 ) . The study aim evaluate progressive increase intermittent treatment discontinuation 3 month able improve QoL outcome respect `` fixed '' intermittent administration TKIs ( control arm ) maintain MR3.0 / MR4.0 molecular response . Patients ' self report EORTC QLQ-C30 outcome measure assess throughout three year follow period . The QoL result trial present accordance high methodological quality criterion document patient-reported outcome ( PRO ) data RCTs , include CONSORT PRO recommendation . Furthermore , study could give additional clinical biological information optimize TKIs therapy elderly .</brief_summary>
	<brief_title>Optimization TKIs Treatment Quality Life Ph+ CML Patients ≥60 Years Deep Molecular Response</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Patients confirm diagnosis Ph+ CML CP 2 . Age ≥ 60 year old 3 . Stable MR3.0/ MR4.0 least 2 year treatment standard ( daily administration ) IM , NIL , DAS therapy ; stability molecular response document least 3 consecutive molecular analysis last 12 month . 4 . Having complete QoL baseline evaluation ( i.e. , randomization ) 5 . Written inform consent prior study procedure 1 . Patients Ph+ CML accelerated/blastic phase ( AP/BP ) , late CP previously treat ( i.e . IFNalpha+/ low dose AraC , Hydroxurea , allogeneic stem cell transplantation , etc ) 2 . Age &lt; 60 year old 3 . Less 2 year treatment standard ( continuous administration ) IM , NIL DAS therapy 3 . Absence stable MR3.0/MR4.0 document least 3 consecutive molecular analysis last 12 month 4 . No write informed consent prior study procedure . 5 . Having kind psychiatric disorder major cognitive dysfunction hamper QoL evaluation ( judged physician ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>